TOP STORY A New Ground Zero for Prostate Cancer A type of prostate cell that has been largely ignored by cancer researchers can, in fact, trigger malignant prostate cancer. [Press release from Howard Hughes Medical Institute discussing online prepublication in Science]
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal) LABORATORY RESEARCH Identification of a Cell of Origin from Human Prostate Cancer Here, scientists show that basal cells from primary benign human prostate tissues can initiate prostate cancer in immunodeficient mice. [Nature] 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo In this study, investigators reported the preparation of 89Zr-desferrioxamine B (DFO)-J591, a novel 89Zr-labeled monoclonal antibody construct for targeted immunoPET and quantification of prostate-specific membrane antigen expression in vivo. [J Nucl Med] Cannabinoid Receptor Dependent and Independent Anti-Proliferative Effects of Omega-3 Ethanolamides in Androgen Receptor Positive and Negative Prostate Cancer Cell Lines Findings suggest that the expression of cannabinoid receptors and of fatty acid amide hydrolase in some tumour cells could well influence the effectiveness of docosahexaenoic acid and eicosapentaenoic acid or their ethanolamide derivatives as anticancer agents. [Carcinogenesis] Effects of Titanocene Dichloride Derivatives on Prostate Cancer Cells, Specifically DNA Damage-Induced Apoptosis In this study, the effects of novel derivatives of titanocene dichloride on prostate cancer cell lines have been investigated. [Prostate] Characterisation of Prostate Cancer Lesions in Heterozygous Men1 Mutant Mice Using immunostaining for the androgen receptor and p63, scientists demonstrated that the menin-negative prostate cancer cells did not display p63 expression and that the androgen receptor was expressed but more heterogeneous in prostate cancer lesions. [BMC Cancer] Short Rare hTERT-VNTR 2-2nd Alleles are Associated with Prostate Cancer Susceptibility and Influence Gene Expression The hTERT (human telomerase reverse transcriptase) gene contains five variable number tandem repeats (VNTR) and previous studies have described polymorphisms for hTERT-VNTR2-2nd. Researchers investigated how allelic variation in hTERT-VNTR2-2nd may affect susceptibility to prostate cancer. [BMC Cancer] Supramolecular Hydrogel Capsule Showing Prostate Specific Antigen-Responsive Function for Sensing and Targeting Prostate Cancer Cells Investigators constructed the functional SH-capsule 1/2 that can release a model fluorescent drug triggered by prostate specific antigen (PSA)-catalyzed proteolysis. Selective release of the fluorescent substance was exploited to both assay PSA activity and detect prostate cancer (PCa) cells. They also demonstrated that the released fluorescent substance was delivered and internalized into the PCa cells, mediated by binding to the membrane-bound protein prostate-specific membrane antigen, which is over-expressed on a plasma membrane of the PCa cells. [Chem Sci] CLINICAL RESEARCH Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer In this double-blind, placebo-controlled, multicenter phase 3 trial, researchers randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. [N Engl J Med] Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/mL Most men diagnosed as having prostate cancer with a prostate-specific antigen threshold below 4.0 ng/mL had low-risk disease but underwent aggressive local therapy. Lowering the biopsy threshold but retaining the inability to distinguish indolent from aggressive cancers might increase the risk of overdiagnosis and overtreatment. [Arch Intern Med] Dynamic Contrast-enhanced CT for Cancer: Relationship Between Image Noise, Voxel Size, and Repeatability The purpose of the study was to evaluate the relationship between image noise, voxel size, and voxel-wise repeatability of a dynamic contrast agent–enhanced computed tomographic (CT) examination for prostate cancer. [Radiology] Efficient Assessment of the Most Important Symptoms in Advanced Prostate Cancer: the NCCN/FACT-P Symptom Index In line with recent regulatory guidance on the development of patient-reported outcomes, investigators undertook a multistep/multistudy approach to develop and test a new symptom index (NCCN FACT-Prostate Symptom Index-17) that can be used to examine the effectiveness of noncurative treatments in advanced prostate cancer. [Psychooncology]
|
POLICY NEWS Brussels to Invest $8.3 Billion in Research Research organizations, universities, and industry will receive a sum of 6.4 billion euros next year in the European Commission’s largest ever allocation for research and innovation. [European Commission, European Union] Consumer Gene Test Results Misleading – U.S. Probe People who send off their saliva to genetic testing companies to find out their risk for prostate cancer or diabetes are likely to get different results, depending on the company they choose, government investigators told lawmakers. [Government Accountability Office, United States] FDA and Other Federal Agencies Collaborate to Improve Chemical Screening The Tox21 collaboration merges federal agency resources (research, funding and testing tools) to develop ways to more effectively predict how chemicals will affect human health and the environment. [Food and Drug Administration, United States] Gene-Testing Companies May Need U.S. Regulators Review, FDA Letters Say The U.S. Food and Drug Administration sent letters to gene-testing companies saying the tests “appear to meet the definition of a device.” [Food and Drug Administration, United States] NIH Asks for Input on Closing Loophole in Conflict-of-Interest Rule Responding to yet another flap about the influence of drug companies on biomedical research, the National Institutes of Health (NIH) has decided it needs more time to revise its rules for policing conflicts of interest so that sanctions will move with an investigator if he or she changes institutions. [National Institutes of Health, United States] Office of Biotechnology Activities; Recombinant DNA Research: Proposed Action Under the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) (Doc. 2010-17668) [National Institutes of Health, United States] National Institute of General Medical Sciences; Notice of Closed Meeting (Doc. 2010-18088) [National Institutes of Health, United States] Center for Scientific Review; Notice of Closed Meeting (Doc. 2010-18052) [National Institutes of Health, United States] Genomics of Transplantation Cooperative Research Program (U01, U19) (RFA-AI-10-019) [National Institutes of Health, United States] Instrument Development for Biomedical Applications (R21) (RFA-RR-10-009) [National Institutes of Health, United States] Biosafety in Microbiological and Biomedical Laboratories (BMBL): 5th Edition (NOT-OD-10-117) [National Institutes of Health, United States] Bioengineering Research Partnerships (BRP)[R01] (PAR-10-234) [National Institutes of Health, United States] National Institute of Biomedical Imaging and Bioengineering Program Project (P01) Applications (PAR-10-233) [National Institutes of Health, United States] Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding Is Sought and Responsible Prospective Contractors [Docket Number NIH-2010-0001] [Department of Health and Human Services, United States]
|
EVENTS (Listed by Date) 2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2) August 2-4, 2010 Singapore City, Singapore 9th Mount Desert Island Stem Cell Symposium August 6-7, 2010 Salsbury Cove, United States Australian-Canadian Prostate Cancer Research Alliance Symposium August 6-8, 2010 Gold Coast, Australia NEW 11th National Prostate Cancer Symposium August 11-13, 2010 Melbourne, Australia CHI’s 5th Annual Immunotherapeutics and Vaccine Summit (ImVacS) August 17-19, 2010 Cambridge, United States 2010 World Cancer Congress August 18-21, 2010 Shenzhen, China Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA) August 23-27, 2010 Toronto, Canada Select Biosciences Inaugural Cellular Therapy Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences 2nd Annual World Biobanking Summit August 24-25, 2010 Edinburgh, Scotland Select Biosciences 3rd Annual Stem Cells Europe Conference August 24-25, 2010 Edinburgh, Scotland 28th World Congress of Endourology and SWL September 1-4, 2010 Chicago, United States Prostate Cancer Research Institute Conference 2010 September 11-12, 2010 California, United States International Society for Cellular Therapy (ISCT) – Europe 2nd Regional Meeting September 11-14, 2010 Belgirate, Italy Tissue Engineering and Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010 September 15-17, 2010 Sydney, Australia NEW 2010 Prostate Cancer Canada (PCCN) Conference September 22-25, 2010 Toronto, Canada 35th European Society for Medical Oncology (ESMO) Congress October 8–12, 2010 Milan, Italy Frontiers in Tumour Progression October 24-27, 2010 Madrid, Spain Cancer Pharmacogenetics: Personalising Medicine November 22-24, 2010 Madrid, Spain Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News. Visit here to post your career opportunities.
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or Suggestions? Email info@connexoncreative.com with your feedback. |
|
|